Special Issue

Potential Applications of NRF2 Modulators in Therapy

Message from the Guest Editor

Nuclear factor erythroid 2-related factor 2 (Nrf2) is considered the master regulator of the cytoprotective response in cells. Activated by reactive oxygen species and other toxic stimuli, Nrf2 elicits a plethora of beneficial effects that reduce inflammation and oxidative stress, promote mitochondrial function and enhance autophagy, amongst others. Given the positive broad-spectrum effect of Nrf2 activation, stimulating the Nrf2 pathway in disease is of growing interest. This Special Issue will explore the potential application of Nrf2 pharmacological modulators in novel disease states and provide updates on the role of Nrf2 in health and disease to further our understanding of Nrf2 therapeutics and their clinical application.

Guest Editor

Dr. Cara Timpani

- 1. Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia
- Institute for Musculoskeletal Science (AIMSS), Inherited and Acquired Myopathy Program, Victoria University, St Albans, VIC 3021, Australia
- 3. Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, Melbourne, VIC 3021, Australia

Deadline for manuscript submissions

closed (28 February 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/100249

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

